Switch theme
Sign up to access all valuation multiples
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
2018
1.1K+
LTM Revenue $557M
LTM EBITDA $158M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alvotech has a last 12-month revenue (LTM) of $557M and a last 12-month EBITDA of $158M.
In the most recent fiscal year, Alvotech achieved revenue of $490M and an EBITDA of -$32.3M.
Alvotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alvotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $557M | XXX | $490M | XXX | XXX | XXX |
| Gross Profit | $351M | XXX | $304M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $158M | XXX | -$32.3M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | -7% | XXX | XXX | XXX |
| EBIT | $119M | XXX | $69.6M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | -$94.2M | XXX | -$232M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -47% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alvotech's stock price is $11.
Alvotech has current market cap of $3.5B, and EV of $4.6B.
See Alvotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $3.5B | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alvotech has market cap of $3.5B and EV of $4.6B.
Alvotech's trades at 9.5x EV/Revenue multiple, and -144.0x EV/EBITDA.
Equity research analysts estimate Alvotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alvotech has a P/E ratio of -36.7x.
See valuation multiples for Alvotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.5B | XXX | $3.5B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | 29.5x | XXX | -144.0x | XXX | XXX | XXX |
| EV/EBIT | 39.0x | XXX | 66.7x | XXX | XXX | XXX |
| EV/Gross Profit | 13.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -36.7x | XXX | -14.9x | XXX | XXX | XXX |
| EV/FCF | -36.7x | XXX | -15.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlvotech's last 12 month revenue growth is 38%
Alvotech's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Alvotech's rule of 40 is -502% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alvotech's rule of X is 122% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alvotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 76% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -502% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 122% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alvotech acquired XXX companies to date.
Last acquisition by Alvotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Alvotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alvotech founded? | Alvotech was founded in 2018. |
| Where is Alvotech headquartered? | Alvotech is headquartered in United States of America. |
| How many employees does Alvotech have? | As of today, Alvotech has 1.1K+ employees. |
| Who is the CEO of Alvotech? | Alvotech's CEO is Mr. Robert Wessman. |
| Is Alvotech publicy listed? | Yes, Alvotech is a public company listed on NAS. |
| What is the stock symbol of Alvotech? | Alvotech trades under ALVO ticker. |
| When did Alvotech go public? | Alvotech went public in 2022. |
| Who are competitors of Alvotech? | Similar companies to Alvotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alvotech? | Alvotech's current market cap is $3.5B |
| What is the current revenue of Alvotech? | Alvotech's last 12 months revenue is $557M. |
| What is the current revenue growth of Alvotech? | Alvotech revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of Alvotech? | Current revenue multiple of Alvotech is 8.3x. |
| Is Alvotech profitable? | Yes, Alvotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alvotech? | Alvotech's last 12 months EBITDA is $158M. |
| What is Alvotech's EBITDA margin? | Alvotech's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Alvotech? | Current EBITDA multiple of Alvotech is 29.5x. |
| What is the current FCF of Alvotech? | Alvotech's last 12 months FCF is -$127M. |
| What is Alvotech's FCF margin? | Alvotech's last 12 months FCF margin is -23%. |
| What is the current EV/FCF multiple of Alvotech? | Current FCF multiple of Alvotech is -36.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
